Agenus recently presented compelling survival data for the botensilimab and balstilimab combination

Agenus recently presented compelling survival data for the botensilimab and balstilimab combination in advanced MSS colorectal cancer at the European Society for Medical Oncology Gastrointestinal (ESMO−GI) Congress. The late breaking oral presentation highlighted the potential efficacy of this therapeutic duo, showcasing promising results that could signify a breakthrough in treating this challenging form of cancer. The data presented demonstrated significant survival benefits, underlining the potential of these therapies to extend the lives of patients with advanced MSS colorectal cancer.In recognition of the promising clinical activity observed in early studies, the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for botensilimab and balstilimab for the treatment of advanced MSS colorectal cancer. This designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.